Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma.

Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, Yang Z, Cai J, Li H, Chen J, Zhong S, Mohanti SR, Lopez-Soler R, Millis JM, Huang J, Zhang H.

Gut. 2010 Dec;59(12):1687-93. doi: 10.1136/gut.2010.214916. Epub 2010 Sep 28.

PMID:
20876776
2.

[Detection and evaluation of serum GP73, a resident Golgi glycoprotein, as a marker in diagnosis of hepatocellular carcinoma].

Zhao XY, Li N, Ding HG, Jiang FF.

Zhonghua Zhong Liu Za Zhi. 2010 Dec;32(12):943-5. Chinese.

PMID:
21223806
3.

GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.

Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM.

J Hepatol. 2005 Dec;43(6):1007-12. Epub 2005 Jun 28.

PMID:
16137783
4.

Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.

Wang Y, Yang H, Xu H, Lu X, Sang X, Zhong S, Huang J, Mao Y.

J Gastroenterol Hepatol. 2014 Mar;29(3):597-602. doi: 10.1111/jgh.12461.

PMID:
24236824
5.

[Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study].

Mao YL, Yang HY, Xu HF, Sang XT, Lu X, Yang ZY, Zhang JC, Zhong SX, Huang JF, Zhang HB.

Zhonghua Yi Xue Za Zhi. 2008 Apr 8;88(14):948-51. Chinese.

PMID:
18756964
6.

Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.

Wu C, Wang Z, Liu L, Zhao P, Wang W, Yao D, Shi B, Lu J, Liao P, Yang Y, Zhu L.

J Gastroenterol Hepatol. 2009 Jan;24(1):55-62. doi: 10.1111/j.1440-1746.2008.05580.x. Epub 2008 Sep 24.

PMID:
18823443
7.

[Value of combined detection of GP73 and alpha-fetoprotein in diagonosis of hepatocellular carcinoma].

Wu QP, Xie FY, Meng QL, Mu YY.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012 Apr;26(2):148-9. Chinese.

PMID:
23002561
8.

Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.

Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N.

Ann Surg Oncol. 2009 Oct;16(10):2795-804. doi: 10.1245/s10434-009-0618-y. Epub 2009 Aug 11.

PMID:
19669841
9.

Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis.

Zhou Y, Yin X, Ying J, Zhang B.

BMC Cancer. 2012 Jan 16;12:17. doi: 10.1186/1471-2407-12-17. Review.

10.

Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.

Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P.

J Gastroenterol Hepatol. 2010 Jan;25(1):129-37. doi: 10.1111/j.1440-1746.2009.05988.x. Epub 2009 Sep 27.

PMID:
19793164
11.

[Serum arginase activity in patients with liver cirrhosis and hepatocellular carcinoma].

Chrzanowska A, Mielczarek-Puta M, Skwarek A, Krawczyk M, Barańczyk-Kuźma A.

Wiad Lek. 2007;60(5-6):215-8. Polish.

PMID:
17966882
12.

[Expression profiles and differential diagnostic value of serum Golgi protein-73 in patients with liver cirrhosis and primary hepatic carcinoma].

Yang Y, Xiao L, Mao R, Zhang H, Wen H, Zhao HR, He FP, Zhang YF, Bao YX.

Zhonghua Gan Zang Bing Za Zhi. 2012 Dec;20(12):920-4. doi: 10.3760/cma.j.issn.1007-3418.2012.12.010. Chinese.

PMID:
23522254
13.

Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma.

Ozkan H, Erdal H, Tutkak H, Karaeren Z, Yakut M, Yüksel O, Köklü S.

Digestion. 2011;83(1-2):83-8. doi: 10.1159/000320379. Epub 2010 Oct 30. Retraction in: Özkan H, Erdal H, Tutkak H, Karaeren Z, Yakut M, Yüksel O, Köklü S. Digestion. 2012;86(1):66.

PMID:
21042019
14.

Serum golgi phosphoprotein 2 level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma.

Li X, Wu K, Fan D.

Hepatology. 2009 Nov;50(5):1682. doi: 10.1002/hep.23244. No abstract available.

PMID:
19739256
15.

Diagnostic clues for recurrent hepatocellular carcinoma: comparison of tumour markers and imaging studies.

Ando E, Tanaka M, Yamashita F, Kuromatsu R, Takada A, Fukumori K, Yano Y, Sumie S, Okuda K, Kumashiro R, Sata M.

Eur J Gastroenterol Hepatol. 2003 Jun;15(6):641-8.

PMID:
12840676
16.

Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.

Soga K, Watanabe T, Aikawa K, Toshima M, Shibasaki K, Aoyagi Y.

Hepatogastroenterology. 1998 Sep-Oct;45(23):1737-41.

PMID:
9840138
17.

[Clinical significance and diagnostic value of Golgi-protein 73 in patients with early-stage primary hepatocellular carcinoma].

Bao YX, Yang Y, Zhao HR, Mao R, Xiao L, Zhang YF, Aisiker T, Wen H.

Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):505-8. Chinese.

PMID:
24257301
18.

Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand.

Tangkijvanich P, Tosukhowong P, Bunyongyod P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y.

Southeast Asian J Trop Med Public Health. 1999 Mar;30(1):110-4.

PMID:
10695798
19.

Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.

Gadelhak NA, Gadelhak SA, El-Morsi DA, Abdelaziz MM, Abbas AT, El-Emshaty HM.

Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1417-24.

PMID:
19950803
20.

Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis.

Fabris C, Basso DA, Leandro G, Meggiato T, Elba S, Panozzo MP, Del Favero G, Fogar P, Di Mario F, Naccarato R.

Cancer. 1991 Oct 15;68(8):1795-8.

Supplemental Content

Support Center